Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (3292 companies, A–Z).
On November 3, 2026, Novo Nordisk gave Korro Bio notice that it will terminate their research collaboration and license agreement without cause, effective February 1, 2027. Novo Nordisk did not nominate a second target, and no milestone payments were earned under the agreement. Korro's third-quarter 2026 results showed no collaboration revenue, compared with $1.1 million a year earlier, while the net loss narrowed to $17.5 million from $18.1 million.
Novo Nordisk gave 90 days' notice on November 3, 2026; the termination takes effect February 1, 2027.
Korro's $10.0 million upfront payment and other amounts received are non-refundable, and Korro will not incur early termination penalties.
Collaboration revenue was zero for the quarter ended September 30, 2026, versus $1.1 million a year earlier.
Cash, cash equivalents and marketable securities were $124.8 million at September 30, 2026, with a runway into the second half of 2028.
Nurix Therapeutics said on November 3, 2026 that collaboration partner Sanofi has discontinued the Phase 1 trial of SAR448272, an oral STAT6 degrader, and terminated the program. As a result, Nurix does not expect to receive the development, regulatory and commercial milestone payments or royalties it was eligible for on that program, though it remains eligible for payments on other licensed programs under the Sanofi collaboration.
Sanofi notified Nurix on November 3, 2026 that it is discontinuing the Phase 1 first-in-human trial of SAR448272 and terminating the program
Nurix does not expect any future development, regulatory or commercial milestone payments or royalties tied to SAR448272
Nurix remains eligible for milestones and royalties on other licensed programs, which Sanofi may further develop at its discretion
Once Upon a Farm, PBC held a conference call on November 2, 2026 to update investors on its voluntary recall of all Tractor Wheels flavors and SKUs, after the FDA reported three choking incidents. The company said it has not yet identified a root cause and cannot yet estimate total recall costs or insurance recovery, while Tractor Wheels accounted for about 18% of year-to-date net sales.
As of September 30, 2026, the company had about $106 million in cash and cash equivalents and no outstanding debt.
Up to $95.0 million of additional borrowing capacity under existing credit facilities, subject to borrowing base limits and covenants.
Tractor Wheels represented approximately 18% of total company net sales year-to-date; the company says it is too early to estimate total recall costs.
Full third quarter results are scheduled for November 12, 2026 after market close.
Acumen said the Phase 2 ALTITUDE-AD trial of sabirnetug did not meet its primary endpoint or key secondary endpoints in early Alzheimer's disease. The company plans to cease development of sabirnetug, cut costs and explore strategic options to maximize shareholder value, which removes its lead product candidate from development.
Primary endpoint (iADRS change at 18 months vs. placebo) missed at both 35 mg/kg and 50 mg/kg doses; CDR-SB and other key secondary endpoints not statistically significant
Amyloid plaque reduction was statistically significant at both doses at weeks 36 and 76; ARIA-E observed in about 10% of treated participants
Company plans to cease development, including the open-label extension, and evaluate strategic options including its Enhanced Brain Delivery program
Additional ALTITUDE-AD data expected in the coming weeks, which Acumen does not expect to change the trial's efficacy conclusions
Bristol Myers Squibb told Prothena on October 28, 2026 that it will not advance PRX019 further in the clinic, and the PRX019 license agreement will terminate on January 28, 2027. Under the terminated agreement, Prothena would have been eligible for up to $617.5 million in milestones and tiered royalties, and Bristol Myers Squibb will owe none of these payments. Prothena's separate moponetug collaboration with Bristol Myers Squibb continues.
Bristol Myers Squibb decided not to advance PRX019 after an internal strategic review, notified Prothena on October 28, 2026.
The PRX019 Global License Agreement, signed in May 2024 with an $80 million upfront payment, terminates on January 28, 2027.
Up to $617.5 million in development, regulatory and sales milestones, plus royalties, will not be paid to Prothena.
Bristol Myers Squibb continues developing moponetug, for which Prothena has received $135 million and is eligible for up to $562.5 million more.
Geron Corporation said it will discontinue the Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed or refractory myelofibrosis, following a recommendation from the independent Data Monitoring Committee that the trial was unlikely to meet its primary overall survival endpoint. The company reported no new safety signals that change the known safety profile of imetelstat, and it will analyze the data before sharing findings at a future date.
The independent Data Monitoring Committee advised that the trial was unlikely to meet its primary overall survival endpoint.
The trial evaluated 327 patients with intermediate-2 or high-risk myelofibrosis who were relapsed or refractory to a JAK inhibitor.
No new safety signals were observed that change the known safety profile of imetelstat.
Geron says it will keep growing RYTELO demand in the U.S. and broaden access to eligible LR-MDS patients outside the U.S.
Consolidated Water said permitting delays have moved expected construction start for its Kalaeloa desalination project in Oahu, Hawaii, to the first half of 2027 from late 2026. The company received two approvals but several permits remain outstanding, and the Honolulu Board of Water Supply granted schedule extensions, which shareholders may watch for further timing changes.
Expected construction start moved to first half of 2027, compared with the previous expectation of late 2026.
Approvals received from the State Historic Preservation Division and the Hawaii Department of Health; a Memorandum of Agreement from the State Historic Preservation Division is still outstanding.
In July 2026, the Honolulu Board of Water Supply issued a limited notice to proceed authorizing approximately $6 million for long-lead equipment procurement.
Facility is designed to produce 1.7 million gallons of potable water per day, with a contracted 20-year operating and maintenance term after commissioning.
Tenax Therapeutics temporarily paused enrollment in its LEVEL-2 Phase 3 trial of TNX-103 while it amends the enrollment criteria to target patients with lower baseline 6-minute walk distance, based on results from the LEVEL trial. The company also said it has requested a Type C meeting with the U.S. Food and Drug Administration to discuss the overall development of levosimendan. The pause delays enrollment in a pivotal trial, and the company's investor presentation states that the LEVEL trial did not meet its primary endpoint in the overall population.
Enrollment in LEVEL-2 is paused and may resume at each site as the amended protocol takes effect there.
The amendment targets patients with baseline 6-minute walk distance of 100m to 300m, or above 300m to 400m with a right atrial volume index of 25 mL/m2 or more.
The LEVEL trial's overall primary endpoint difference was 3.5 M (p = 0.63), according to the investor presentation attached as Exhibit 99.1, dated October 8, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.